分子標的/Bio時代のリウマチ・膠原病治療ストラテジー

出版社: 文光堂
著者:
発行日: 2015-10-21
分野: 臨床医学:内科  >  膠原病/リウマチ
ISBN: 9784830620584
電子書籍版: 2015-10-21 (第1版第2刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

11,000 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

11,000 円(税込)

商品紹介

リウマチ専門医,またはそれを志す若手内科医を主な読者対象として,リウマチ・膠原病患者への初診時のアプローチ,患者背景に応じて標準治療を外れる場合の治療選択などを解説した実践書.

目次

  • 分子標的/Bio時代のリウマチ・膠原病治療ストラテジー

    ―目次―

    1章 関節リウマチ
    2章 関節リウマチ類縁疾患
    3章 脊椎関節炎
    4章 全身性エリテマトーデス
    5章 多発性筋炎・皮膚筋炎
    6章 強皮症
    7章 混合性結合組織病
    8章 Sjogren症候群
    9章 抗リン脂質抗体症候群
    10章 血管炎症候群
    11章 結晶誘発性関節炎
    12章 その他の疾患

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 関節リウマチ

P.12 掲載の参考文献
3) Aho K, Koskenvuo M, Tuominen J et al. Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 1986 ; 13 (5) : 899-902
10) Kaufmann J, Kielstein V, Kilian S et al. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 2003 ; 30 (11) : 2350-55
11) Guedes C, Dumont-Fischer D, Leichter-Nakache S et al. Mortality in rheumatoid arthritis. Rev Rhum Engl Ed 1999 ; 66 (10) : 492-8
16) 川人豊. 関節リウマチの最新薬物療法-新分類基準・新寛解基準に準拠して. 医学と看護社, 2012
17) 日本リウマチ学会新基準検証委員会報告 http://www.ryumachi-jp.com/info/news120115.html
21) Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) : a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005 ; 23 (5 Suppl 39) : S100-108
31) 日本呼吸器学会薬剤性肺障害ガイドライン作成委員会編. 薬剤性肺障害の評価, 治療についてのガイドライン. 日本呼吸器病学会, 2006
34) Mori S, Cho I, Koga Y et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008 ; 35 (8) : 1513-21
35) Despaux J, Manzoni P, Toussirot E et al. Prospective study of the prevalence of bronchiectasis in rheumatoid arthritis using high-resolution computed tomography. Rev Rhum Engl Ed 1998 ; 65 (7-9) : 453-61
37) 日本結核病学会非結核性抗酸菌症対策委員会ほか. 肺非結核性抗酸菌症化学療法に関する見解-2012年改訂. Kekkaku 2012 ; 87 (2) : 83-86
43) Jalal H, Curtis JR, Cofield S et al. Cost-Effectiveness Analysis Of Triple Therapy Versus Etanercept Plus Methotrexate In Early Aggressive Rheumatoid Arthritis : Analysis Based On The TEAR Trial. Arthritis & rheumatism 2013 ; 65 (10) (supplement) : S1127
44) Furneri G, Mantovani LG, Belisari A et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012 ; 30 (4 Suppl 73) : S72-84
46) Van Vollenhoven RF, Roy S, Ray S et al. An estimate of indirect cost savings inpatients with early rheumatoid arthritis : sub-analysis of the premier health outcomes companion study [abstract]. Ann Rheum Dis 2008 ; 67 (Suppl II) : 650
47) Bejarano V, Quinn MA, Conaghan PG et al. Improved work stability and reduced job loss with adalimumab plus methotrexate in early rheumatoid arthritis : results of the prevention of work disability (PROWD) study [abstract]. Ann Rheum Dis 2007 ; 66 (Suppl II) : 176
50) 中野正明. 関節リウマチの腎障害に対する留意点. 日本内科学会雑誌 2005 ; 94 (5) : 859-63
52) リウマトレックス(R) 適正使用情報 Vol.19 改訂版
54) Aronoff G, Berns J, Brier M et a1. Drug prescribing in renal failure Dosing guidelines for adults, 4th ed, Arnerican College of Physicians, American Society of Internal Medicine, 1999
P.22 掲載の参考文献
4) Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update. Ann Rheum Dis 2014 ; 73 (3) : 429-509
5) Pincus T, Yazici Y, Sokka T et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003 ; 21 (5 Suppl 31) : S179-85
6) 日本リウマチ学会MTX診療ガイドライン策定小委員会 (編). 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2011年版. 羊土社, 2011
7) Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol 2010 ; 28 (5 Suppl 61) : S52-57
P.30 掲載の参考文献
14) 日本リウマチ学会 関節リウマチ超音波標準化委員会編. リウマチ診療のための関節エコー撮像法ガイドライン. 羊土社, 2011
20) 伊藤聡. 高齢者関節リウマチ. 炎症と免疫 2009 ; 17 (1) : 88-100
22) 日本リウマチ学会MTX診療ガイドライン策定小委員会 (編). 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2011年版. 羊土社, 2011
24) リウマトレックス(R) カプセル2mg 製品添付文書. 2012年7月改訂
25) 日本結核病学会治療委員会. 「結核医療の基準」の見直し-2008年. Kekkaku 2008 ; 83 (7) : 529-35
26) リウマトレックス適正使用情報 Vol 16. 2010
28) http://www.ryumachi-jp.com/info/news110926.html
31) 越智隆弘 (厚生労働省研究班班長) ほか. 関節リウマチの診療マニュアル (改訂版). 診断のマニュアルとEBMに基づく治療ガイドライン. 財団法人日本リウマチ財団, 2004
32) 日本リウマチ学会. 関節リウマチ診療ガイドライン 2014. メディカルレビュー社, 2014
34) 一般社団法人日本リウマチ学会. 関節リウマチ (RA) に対するTNF阻害薬使用ガイドライン (2012年改訂版), 2012
40) Ito S, Sato H, Toyoshima Y et al. Increasing the dose and reducing the dosing intervals of infliximab (IFX) in RA. Mod Rheumatol 2011 ; 21 : s75
41) Ito S, Unno M, Kobayashi D et al. Dose escalation of methotrexate (MTX) in rheumatoid arthritis (RA) patients. Mod Rheumatol 2012 ; 22 : s168
42) Ito S, Oh K, Unno M et al. The decrease in disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate. Mod Rheumatol 2013 ; 23 : s107
P.34 掲載の参考文献
8) 日本リウマチ学会. 関節リウマチ (RA) に対するTNF阻害薬使用ガイドライン (2012年改訂版), http://www.ryumachi-jp.com/
P.37 掲載の参考文献
P.39 掲載の参考文献
1) 日本リウマチ友の会HPより http://www.nrat.or.jp/rheumatism/2010_101.html
10) Glennas A, Kvien TK, Andrup O et al. Recent onset arthritis in the elderly : a 5 year longitudinal observational study. J Rheumatol 2000 ; 27 (1) : 101-8
11) van der Heijde DM, van Riel PL, van Leeuwen MA et al. Older versus younger onset rheumatoid arthritis : results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol 1991 ; 18 (9) : 1285-9
17) The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol 1995 ; 22 (2) : 218-23
20) Fleischmann RM, Baumgartner SW, Tindall EA et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis : a retrospective analysis of clinical trial results. J Rheumatol 2003 ; 30 (4) : 691-6
23) Bathon JM, Fleischmann RM, Van der Heijde D et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006 ; 33 (2) : 234-43
24) http://www.orencia.jp/resource/1438342982000/orencia/report/index.html
25) Salmon JH, Gottenberg JE, Ravaud P et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice : results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis 2015 Jun 5. pii : annrheumdis-2015-207362. doi : 10.1136/annrheumdis-2015-207362 [Epub ahead of print]

2章 関節リウマチ類縁疾患

P.45 掲載の参考文献
2) 血管炎症候群の診療ガイドライン. Circ J 2008 ; 72 (Suppl IV) : 1253-1318
5) Vollertsen RS, Conn DL. Vasculitis associated with rheumatoid arthritis. Rheum Dis Clin North Am 1990 ; 16 (2) : 445-61
P.50 掲載の参考文献
3) Chen DY, Lan JL, Lin FJ et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004 ; 31 (11) : 2189-98
5) Choi JH, Suh CH, Lee YM et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumtol 2003 ; 30 (11) : 2422-27
10) Cavagna L, Caporali R, Epis O et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001 ; 19 (3) : 329-32
13) Ohta A, Yamaguchi M, Tsunematsu T et al. Adult Still's disease : a multicenter survey of Japanese patients. J Rheumatol 1990 ; 17 (8) : 1058-63
14) Riera E, Olive A, Narvaez J et al. Adult onset Still's disease ; review of 41 cases. Clin Exp Rheumatol 2011 ; 29 (2) : 331-6
15) Yamaguchi M, Ohta A, Tsunematsu T et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992 ; 19 (3) : 424-30
18) Fautrel B, Borget C, Rozenberg S et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 1999 ; 26 (2) : 373-8
19) Marchesoni A, Ceravolo GP, Battafarano N et al. Cyclosporin A in the treatment of adult onset Still's disease. J Rheumatol 1997 ; 24 (8) : 1582-7
22) Jung JH, Jun JB, Yoo DH et al. High toxicity of sulfasalazine in adult-onset Still's disease. Clin Exp Rheumatol 2000 ; 18 (2) : 245-8
30) Kraetsch HG, Antoni C, Kalden JR et al. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab : first experiences. Ann Rheum Dis 2001 ; 60 (Suppl 3) : iii55-iii57
33) Vignes S, Wechsler B, Amoura Z et al. Intravenous immunoglobulin in adult Still's disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998 ; 16 (3) : 295-8
P.57 掲載の参考文献
7) Spies CM, Burmester GR, Buttgereit F. Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica. Clin Exp Rheumatol 2010 ; 28 (5 Suppl 61) : S172-7
9) Caporali R, Cimmino MA, Montecucco C et al. Glucocorticoid treatment of polymyalgia rheumatic. Clin Exp Rheumatol 2011 ; 29 (5 Suppl 68) : S143-7
11) Docken WP. Polymyalgia rheumaica can recur years after discontinuation of corticosteroid therapy. Clin Exp Rheumatol 2009 ; 27 (1 Suppl 52) : S25-27
14) Shimojima Y, Matsuda M, Ishii W et al. Analysis of peripheral blood lymphocytes using flow cytometry in polymyalgia rheumatica, RS3PE and early rheumatoid arthiritis. Clin Exp Rheumatol 2008 ; 26 (6) : 1079-82
18) Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome : followup for neoplasia. J Rheumatol 2005 ; 32 (9) : 1760-61
22) Cantini F, Salvarani C, Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol 1999 ; 17 (6) : 741-4
29) Gonzalez-Lopez L, Gamez-Nava JI, Jhangri GS et al. Prognostic factors for development of rheumatoid arthritis and other connective tissue diseases in patients with palindromic rheumatism. J Rheumatol 1999 ; 26 (3) : 540-45

3章 脊椎関節炎

P.69 掲載の参考文献
9) Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 1990 ; 57 (2) : 85-89
13) Saraux A, Guedes C, Allain J et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J Rheumatol 1999 ; 26 (12) : 2622-7
15) Hukuda S, Minami M, Saito T et al. Spondyloarthropathies in Japan : nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001 ; 28 (3) : 554-9
17) Sherlock JP, Joyce-Shaikh B, Turner SP et al. IL-23 induces spondyloarthropathy by acting on ROR-γ t+ CD3+ CD4- CD8- entheseal resident T cells. Nat Med 2012 ; 18 (7) : 1069-76
34) Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol 1976 ; 5 (1) : 60-64
P.77 掲載の参考文献
11) Hukuda S, Minami M, Saito T et al. Spondyloarthropathies in Japan : nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001 ; 28 (3) : 554-9
15) Amor B, Dougados M, Listrat V et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995 ; 62 (1) : 10-15
18) Mau W, Zeidler H, Mau R et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988 ; 15 (7) : 1109-14
22) Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006 ; 33 (4) : 722-31
35) Glintborg B, Ostergaard M, Krogh NS et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumor necrosis factor α inhibitor therapy : results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013 ; 72 (7) : 1149-55
P.85 掲載の参考文献
3) Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001 ; 28 (8) : 1842-6
28) Kavanaugh AF, Ritchlin CT, GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis : an evidence based approach and basis for treatment guidelines. J Rheumatol 2006 ; 33 : 1417-21
P.93 掲載の参考文献
2) Fiessinger N, Leroy E. Contribution a l'etude d'une epidemie de dysenterie dans le somme. Bull Soc Med Hop Paris 1916 ; 40 : 2030-69
5) Braun J, Kingsley G, van der Heijde D et al. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 2000 ; 27 (9) : 2185-92

4章 全身性エリテマトーデス

P.103 掲載の参考文献
9) Lindau D, Mussard J, Rabsteyn A et al. TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Ann Rheum Dis 2014 ; 73 (12) : 2199-207
15) Urowitz MB, Feletar M, Bruce IN et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005 ; 32 (8) : 1467-72
19) Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35 (6) : 630-40
20) Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005 ; 32 (5) : 824-7
21) Abu-Shakra M, Urowitz MB, Gladman DD et al. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995 ; 22 (7) : 1265-70
22) Symmons DP, Coppock JS, Bacon PA et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988 ; 69 (259) : 927-37
29) Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008 ; 26 (5 Suppl 51) : S72-79
39) Drenkard C, Villa AR, Alarcon-Segovia D et al. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994 ; 21 (6) : 1067-72
40) Abu-Shakra M, Urowatz MB, Gladman DD et al. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995 ; 22 (7) : 1265-70
44) Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999 ; 26 (6) : 1275-9
62) Sjowall C, Sturm M, Dahle C et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J Rheumatol 2008 ; 35 (10) : 1994-2000
65) Meyer O, Piette JC, Bourgeois P et al. Antiphospholipid antibodies : a disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosus (SLE). Comparison with a group of 91 patients with antinuclear antibody positive SLE. J Rheumatol 1987 ; 14 (3) : 502-6
P.111 掲載の参考文献
17) 横川直人. ヒドロキシクロロキン. 日本内科学会雑誌 2011 ; 100 (10) : 2960-5
P.124 掲載の参考文献
14) Ikeuchi H, Hiromura K, Takahashi S et al. Mixed lesion of Membranous (Class V) and Proliferative (Class III/IV) Lupus Nephritis Predicts Poor Renal Prognosis (Abstract). Annual Meetings of American Society of Nephrology 2012 ; 714A
15) Kidney Disease : Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Chapter 12 : Lupus nephritis. Kidney Int Suppl (2011) 2012 ; 2 (2) : 221-32
19) Hara R, Miyazawa H, Nishimura K et al. A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. Mod Rheumatol, Epub 2015 Jul 28
37) Furie R, Nicholls K, Cheng TT et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis : results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study [abstract]. Arthritis Rheum 2011 ; 63 (Suppl) : S962-3
57) Falk RJ, Schur PH, Appel GB. Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis. In : UpToDate, Forman, JP (Ed) Waltham, MA 2013
59) 本間光夫, 市川陽一, 秋月正史ほか. ループス腎炎に対するメチルプレドニゾロンパルス療法と経口プレドニゾロン療法の二重盲検群間比較試験. リウマチ 1994 ; 34 (3) : 616-27
62) Sloan RP, Schwartz MM, Korbet SM et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996 ; 7 (2) : 299-305
P.135 掲載の参考文献
3) Hanly JG, Urowitz MB, O'Keeffe AG et al. Headache in systemic lupus erythematosus : results from a prospective, international inception cohort study. Arthritis Rheum 2013 ; 65 (11) : 2887-97
15) Asherson RA, Hughes GR. Antiphospholipid antibodies and chorea. J Rheumatol 1988 ; 15 (2) : 377-9
34) 廣畑俊成. 第2章 難治性神経筋疾患 I. CNSループス. 厚生労働科学免疫アレルギー疾患予防・治療研究事業 全身性自己免疫疾患における難治性病態の診断と治療に関する研究「全身性自己免疫疾患における難治性病態の診療ガイドライン」, 2005, 5-9
38) 廣畑俊成. ループス精神病の既存治療法の評価に関する研究 (中枢神経障害小委員会報告). 厚生労働科学研究補助金 免疫アレルギー疾患予防・治療等研究事業 免疫疾患の既存治療法の評価とその合併症に関する研究, 田中良哉班長, 平成17年-平成19年度 綜合研究報告, 2008, 38-41
P.147 掲載の参考文献
4) 亀崎豊実, 梶井英治. 特集 骨髄不全症候群 (特発性増血障害 : 診断と治療の進歩 自己免疫性溶血性貧血). 日本内科学会雑誌 2012 ; 101 : 1960-68
22) 桑名正隆. 抗トロンボポエチン受容体抗体と無巨核球性血小板減少症. 医学のあゆみ 2012 ; 242 (8) : 584-8
30) Cervera H, Jara LJ, Pizarro S et al. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome. J Rheumatol 1995 ; 22 (10) : 1867-71
31) Arnal C, Piette JC, Leone J et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus : 59 cases. J Rheumatol 2002 ; 29 (1) : 75-83
37) Lindholm C, Borjesson-Asp K, Zendjanchi K et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008 ; 35 (5) : 826-33
46) Euler HH, Harten P, Zeuner RA et al. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997 ; 24 (11) : 2153-7
52) 勝又康弘, 岡本完, 針谷正祥ほか. 全身性強皮症を基礎疾患とした血球貪食症候群 (HPS) にEtoposideが著効した1症例. リウマチ 2002 ; 42 (5) : 820-26
54) 藤村吉博. 血栓性血小板減少性紫斑病. 臨床血液 2012 ; 53 (2) : 185-95
56) 藤村吉博. TTP の診断と治療. 日本血栓止血学会誌 2008 ; 19 (3) : 358-62
58) 宮村知也, 渡邉秀之, 高濱宗一郎ほか. 血栓性血小板減少性紫斑病を合併した全身性エリテマトーデスの臨床的検討. 日本臨床免疫学会会誌 2008 ; 31 (3) : 159-65
P.156 掲載の参考文献

5章 多発性筋炎・皮膚筋炎

P.168 掲載の参考文献
7) Tjarnlund A. Progress Report On Development of Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies ; the American College of Rheumatology Scientific Meeting 2012 (Abstract # 753)
37) Kotani T, Makino S, Takeuchi T et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008 ; 35 (2) : 254-9
P.178 掲載の参考文献
2) Tanimoto K, Nakano K, Kano S et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995 ; 22 (4) : 668-74
4) Tjarnlund A, Alfredsson L, Amato, AA et al. Progress Report On Development of Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies : the American College of Rheumatology Scientific Meeting 2012 (Abstract # 753)
6) Olsen NJ, Wortmann RL. Inflammatory and metabolic disease of muscle. Primer of Rheumatic Diseases, 11a ed, Klippel JH ed, Georgia : Arthritis Foundation 1997, 276-82
10) Lee W, Zimmermann B 3rd, Lally EV. Relapse of polymyositis after prolonged remission. J Rheumatol 1997 ; 24 (8) : 1641-4
12) Adams EM, Plotz PH. The treatment of myositis. How to approach resistant disease. Rheum Dis Clin North Am 1995 ; 21 (1) : 179-202
13) Miller FW. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am 1994 ; 20 (4) : 811-26
16) 宮坂信之 (自己免疫疾患の病因・病態解析と新たな治療法の開発に関する調査研究班). 皮膚筋炎及び多発性筋炎. 疾病対策研究会編集「難病の診断と治療指針 改訂版」, 六法出版社, 2001, 87-93
19) Nzeusseu A, Brion F, Lefebvre C et al. Functional outcome of myositis patients : can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol 1999 ; 17 (4) : 441-6
20) Oddis CV, Medsger TA Jr. Relationship between serum creatine kinase level and corticoid therapy in polymyositis-dermatomyositis. J Rheumatol 1988 ; 15 (5) : 807-11
21) Huang JL. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenouzs methylprednisolone pulse therapy. Clin Exp Rheumatol 1999 ; 17 (5) : 621-4
27) 伊東友好, 光岡茂樹, 宇治正人ほか. 少量のメソトレキセートの併用が有効と考えられた間質性肺炎を伴う皮膚筋炎の1例. 日呼吸会誌 1999 ; 37 (8) : 636-40
30) Kono DH, Klashman DJ, Gilbert RC. Successful IV pulse cyclophosphamide in refractory PM in 3 patients with SLE. J Rheumatol 1990 ; 17 (7) : 982-3
31) Cronin ME, Miller FW, Hicks JE et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989 ; 16 (9) : 1225-8
32) Grau JM, Herrero C, Casademont J et al. Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol 1994 ; 21 (2) : 381-2
33) Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis : population based experience in 6 patients and literature review. J Rheumatol 2000 ; 27 (12) : 2855-9
38) Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestation of dermatomyositis : a series of 4 cases. J Rheumatol 2000 ; 27 (6) : 1542-5
44) 柏崎禎夫, 針谷正祥, 木下真男ほか. ステロイド抵抗性多発性筋炎/皮膚筋炎に対するガンマグロブリン大量静脈注射療法の検討. 厚生省特定疾患免疫疾患調査研究班 平成8年度研究報告書, 1997 ; 201-3
47) Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009 ; 27 (6) : 1009-16
53) Iannone F, Scioscia C, Falappone PC et al. Use of etanercept in the treatment of dermatomyositis : a case series. J Rheumatol 2006 ; 33 (9) : 1802-4
P.191 掲載の参考文献
6) Kameda H, Nagasawa H, Ogawa H et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005 ; 32 (9) : 1719-26
14) Kotani T, Makino S, Takeuchi T et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008 ; 35 (2) : 254-9
17) Labirua-Iturburu A, Selva-O'Callaghan A, Martinez-Gomez X et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 2013 ; 31 (3) : 436-9
21) アステラス製薬 社内報告書 (多発性筋炎・皮膚筋炎に合併する間質性肺炎患者・医師主導治験) (DIR130022)
53) Tang R, Millett CR, Green JJ. Amyopathic dermatomyositis complicated by pneumomediastinum. J Clin Aesthet Dermatol 2013 ; 6 (3) : 40-43
57) Pilkington C, Tjarnlund A, Bottai M et al. Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. (pages S70-S71) Article first published online : 27 Mar 2014, Doi : 10.1002/art.38463
P.198 掲載の参考文献
1) Stertz G. Polymyositis. Berl Klin Wochenschr 1916 ; 53 : 489
9) 新井達, 楠舞, 桑原慎治ほか. 悪性腫瘍を合併した皮膚筋炎の臨床的検討. 日本皮膚科学会雑誌 2010 ; 120 (6) : 1197-202
22) 青墳章代, 服部孝道. 傍腫瘍性皮膚筋炎. 日本臨床別冊 領域別症候群シリーズ NO29, 神経症候群 IV, 日本臨床社, 2000 ; 373-6
23) 佐藤賢一郎, 塚本健一, 佐藤太一ほか. 皮膚筋炎合併卵巣癌に対するneoadjuvant chemotherapyの経験. 臨床婦人科産科 1999 ; 53 (3) : 335-9
27) 濱田円, 市川純一, 伊藤充矢ほか. 早期胃癌, 大腸癌同時性重複癌を合併した皮膚筋炎の1例. 日消外会誌 2003 ; 36 (8) : 1178-82
28) Callen, JP. Dermatomyositis and malignancy-A continuing controversy. Cancer Bull 1983 ; 35 : 277-80
29) Callen JP. Myositis and malignancy. Clin Rheum Dis 1984 ; 10 (1) : 117-30
31) 伊藤正朗, 加瀬肇, 河野明彦ほか. 皮膚筋炎にγ-グロブリン製剤が有効であった胃・大腸重複癌の1手術例. 日消外会誌 2005 ; 38 (2) : 157-62

6章 強皮症

P.208 掲載の参考文献
15) Lam AP, Flozak AS, Russell S et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol 2011 ; 45 (5) : 915-22
17) Lam AP, Gottardi CJ. β-catenin signaling : a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol 2011 ; 23 (6) : 562-7
31) Silver RM, Warrick JH, Kinsella MB et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993 ; 20 : 838-44
32) Varai G, Earle L, Jimenez SA et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998 ; 25 : 1325-9
46) Wigley FM, Korn JH, Csuka ME et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis : a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998 ; 41 (4) : 670-77
P.217 掲載の参考文献
3) Myers SL, Cohen JS, Sheets PW et al. B-mode ultrasound evaluation of skin thickness in progressive systemic sclerosis. J Rheumatol 1986 ; 13 (3) : 577-80
4) Bjerring P. Skin elasticity measured by dynamic admittance. A new technique for mechanical measurements in patients with scleroderma. Acta Derm Venereol Suppl (Stockh) 1985 ; 120 : 83-87
5) Ballou SP, Mackiewicz A, Lysikiewicz A et al. Direct quantitation of skin elasticity in systemic sclerosis. J Rheumatol 1990 ; 17 (6) : 790-94
9) Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis : an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993 ; 20 (11) : 1892-6
10) Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995 ; 22 (7) : 1281-5
11) Medsger TA Jr, Silman AJ, Steen VD et al. A disease severity scale for systemic sclerosis : development and testing. J Rheumatol 1999 ; 26 (10) : 2159-67
12) 厚生労働省強皮症調査研究班. 強皮症における診断基準・重症度分類・治療指針 2007改訂版. 厚生労働科学研究費難治性疾患克服事業
14) Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 2004 ; 22 (3 Suppl 33) : S87-89
34) Vanthuyne M, Blockmans D, Westhovens R et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007 ; 25 (2) : 287-92
50) Lam GK, Hummers LK, Woods A et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007 ; 34 (7) : 1636-7
56) Isaacs JD, Hazleman BL, Chakravarty K et al. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 1996 ; 23 (6) : 1103-6
61) Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial : intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 2013 ; 31 (2 Suppl 76) : 151-6
P.226 掲載の参考文献
12) Launay D, Remy-Jardin M, Michon-Pasturel U et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006 ; 33 (9) : 1789-801
34) Kim HG, Tashkin DP, Clements PJ et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 2010 ; 28 (5 Suppl 62) : S26-35
42) Sfriso P, Cozzi F, Oliviero F et al. CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis. Clin Exp Rheumatol 2012 ; 30 (2 Suppl 71) : S71-75
59) Silver RM, Warrick JH, Kinsella MB et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993 ; 20 (5) : 838-44
60) Varai G, Earle L, Jimenez SA et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998 ; 25 (7) : 1325-9
61) Pakas I, Ioannidis JP, Malagari K et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002 ; 29 (2) : 298-304
63) Airo P, Danieli E, Rossi M et al. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis : results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 2007 ; 25 (2) : 293-6
65) Berezne A, Ranque B, Valeyre D et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis : a retrospective multicenter open-label study. J Rheumatol 2008 ; 35 (6) : 1064-72
75) Broad K, Pope JE. The efficacy of treatment for systemic sclerosis interstitial lung disease : results from a meta-analysis. Med Sci Monit 2010 ; 16 (9) : RA187-90
80) Vanthuyne M, Blockmans D, Westhovens R et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007 ; 25 (2) : 287-92
92) Daoussis D, Liossis SN, Tsamandas AC et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012 ; 30 (2 Suppl 71) : S17-22
115) Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener's granulomatosis : incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008 ; 35 (1) : 100-105
P.242 掲載の参考文献
2) 肺高血圧症治療ガイドライン (2012年改訂版). 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告), 2014
11) 吉田俊治, 深谷修作. 膠原病性肺高血圧症の頻度と病態の解析 厚生労働科学研究費補助金免疫アレルギー疾患予防・治療研究事業全身性自己免疫疾患における難治性病態の診断治療法に関する研究. 平成15年度総括・分担研究報告書, 40-43, 2004
23) 全身性強皮症診療ガイドライン作成委員会. 全身性強皮症診療ガイドライン2010. 2010
P.251 掲載の参考文献
2) 遠藤平仁. 腎病変. 全身性強皮症診療ガイドライン, 全身性強皮症診療ガイドライン作成委員会, 2010, 57-63
9) Walker KM, Pope J ; participating members of the Scleroderma Clinical Trials Consortium (SCTC) ; Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications : what to use when first-line treatment fails--a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012 ; 42 (1) : 42-55
12) Steen VD, Syzd A, Johnson JP et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005 ; 32 (4) : 649-55
14) Endo H, Hosono T, Kondo H. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol 1994 ; 21 (5) : 864-70
15) 三森明夫, 奈良浩之, 金子尚子ほか. 微小血管傷害性溶血性貧血と血小板減少を示した全身性強皮症の3例. 日本臨床免疫学会誌 2000 ; 23 (1) : 57-63
18) Mannucci PM, Vanoli M, Forza I et al. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003 ; 88 (8) : 914-8
25) Hasegawa S, Iesato K, Tsukahara T et al. Successful use of angiotensin II receptor antagonist (losartan) in a patient with scleroderma renal crisis]. Nihon Jinzo Gakkai Shi 2000 ; 42 (2) : 60-65
P.254 掲載の参考文献
4) Jinnin M, Ihn H, Yamane K et al. Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis. Clin Exp Rheumatol 2003 ; 21 : 91-94
6) 佐藤伸一ほか. 全身性強皮症診療ガイドライン. 強皮症調査研究班事務局, 2010
10) Lam GK, Hummers LK, Woods A et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007 ; 34 (7) : 1636-7
P.256 掲載の参考文献
12) 平松佳子, 武田則之, 奥村昇司ほか. 著明な胸水, 心嚢液貯留を認めた超高齢者進行性全身性硬化症の1例. 日本老年医学会雑誌 1996 ; 33 (7) : 535-9
P.258 掲載の参考文献
1) McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians ; American Thoracic Society, Inc. ; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009 ; 53 (17) : 1573-619
6) 吉田俊治, 深谷修作. 混合性結合組織病の病態解明と治療法の確立に関する研究 混合性結合組織病 (MCTD) に合併した肺動脈性高血圧症 (PAH) に関する研究. 混合性結合組織病の病態解明と治療法の確立に関する研究 平成19年度 総括・分担研究報告書, 2008, 37-40
10) 佐藤伸一, 藤本学, 桑名正隆ほか. 全身性強皮症診療ガイドライン. 日本皮膚科学会雑誌 2012 ; 122 (5) : 1293-345
11) 三森経世 (編). 混合性結合組織病の治療ガイドライン [改訂第3版]. 厚生労働科学研究費 難治性疾患克服研究事業 混合性結合組織病の病態解明と治療法の確立に関する研究班, 2011, 27-31

7章 混合性結合組織病

P.268 掲載の参考文献
2) 三森経世. 特集 : 内科-100年の歩み (アレルギー・膠原病). III. 主要疾患の歴史. 8. 混合性結合組織病. 日本内科学会雑誌 2002 ; 91 (9) : 2676-82
5) 三森経世 (編). 混合性結合組織病の治療ガイドライン [改訂第3版]. 厚生労働科学研究費 難治性疾患克服研究事業 混合性結合組織病の病態解明と治療法の確立に関する研究班. 2011 ; 27-31
15) Kuwana M, Suzuki H, Takayama S et al. Accelerated hypertension in a patient with mixed connective tissue disease. J Rheumatol 1992 ; 19 (5) : 826-8
17) 大島直紀, 渡辺文絵, 三森経世ほか. 胸膜炎を繰り返し, 胸水中の抗U1RNP抗体および免疫複合体が高値であったMCTD の1例. 日本内科学会雑誌 1994 ; 83 (8) : 1357-8
20) Christopher-Stine L, Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol 2003 ; 30 (12) : 2725-7
22) Tanaka E, Harigai M, Tanaka M et al. Pulmonary hypertension in systemic lupus erythematosus : evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002 ; 29 (2) : 282-7
31) 三森経世, 安岡秀剛, 鈴木美佐子ほか. 混合性結合組織病の髄膜炎. 日本臨床免疫学会会誌 2000 ; 23 (6) : 647-51

8章 Sjogren症候群

P.283 掲載の参考文献
1) 住田孝之 (編). EXPERT膠原病・リウマチ 改訂第3版. 2013, 診断と治療社
12) 日本シェーグレン症候群研究会 (編). シェーグレン症候群の診断と治療マニュアル改訂第2版. 2014, 診断と治療社
23) Gottenberg JE, Cinquetti G, Larroche C et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome : results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013 ; 72 (6) : 1026-31
P.290 掲載の参考文献
9) Murata H, Kita Y, Sakamoto A et al. Limited TCR repertoire of infiltrating T cells in the kidneys of Sjogren's syndrome patients with interstitial nephritis. J Immunol 1995 ; 155 (8) : 4084-9
10) Matsumura R, Umemiya K, Kagami M et al. Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjogren's syndrome. Clin Exp Rheumatol 1998 ; 16 (5) : 561-8
11) Ren H, Wang WM, Chen XN et al. Renal involvement and followup of 130 patients with primary Sjogren's syndrome. J Rheumatol 2008 ; 35 (2) : 278-84
16) 三浦健一郎, 鹿間芳明, 奥山伸彦ほか. 著明な高IgG血症を呈し, 間質性腎炎を合併した原発性シェーグレン症候群の1女児例. 小児科臨床 2004 ; 57 (6) : 1121-5
19) Agrawal S, Bharti V, Jain MN et al. Sjogren's syndrome presenting with hypokalemic periodic paralysis. J Assoc Physicians India 2012 ; 60 : 55-56

9章 抗リン脂質抗体症候群

P.302 掲載の参考文献
3) Kon Y, Atsumi T, Hagiwara H et al. Thrombotic microangiopathy in patients with phosphatidylserine dependent antiprothrombin antibodies and antiphospholipid syndrome. Clin Exp Rheumatol 2008 ; 26 (1) : 129-32
18) 小池隆夫. 抗リン脂質抗体症候群の治療指針案について. 厚生省特定疾患対策研究事業-自己免疫疾患の病因・病態解析と新たな治療法の開発に関する研究報告書 2002 ; 135-7
P.310 掲載の参考文献
14) Kitaori T, Sugiura-Ogasawara M, Ozaki Y et al. Trial for standardization of antiphospholipid antibodies in patients with recurrent pregnancy loss. Lupus in press

10章 血管炎症候群

P.322 掲載の参考文献
19) Clinical Trials. gov Identifier : NCT01791153
P.335 掲載の参考文献
23) Tripathy NK, Chandran V, Garg NK et al. Soluble endothelial cell adhesion molecules and their relationship to disease activity in Takayasu's arteritis. J Rheumatol 2008 ; 35 (9) : 1842-5
42) Valsakumar AK, Valappil UC, Jorapur V et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 2003 ; 30 (8) : 1793-8
P.352 掲載の参考文献
3) Kussmaul A, Maier R. Uber eine bisher nicht beschriebene eigentumlichen Arterienerkrankung (Periarteritis nodosa) die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellahmung einhergeht. Dtsch Arch Klin Med 1866 ; 1 : 484-517
6) 厚生労働省難治性疾患克服研究事業 難治性血管炎に関する調査研究班. 結節性多発動脈炎の診断基準 (2006年改訂)
8) 中林公正, 橋本博史. 結節性多発動脈炎 (結節性動脈周囲炎) -Polyarteritis Nodosa, PN-. 厚生科学研究 特定疾患対策研究事業 難治性血管炎に関する調査研究班 (班長橋本博史) 難治性血管炎の診療マニュアル. キタ・メディア 2002 ; 19-23
10) Arkin A. A Clinical and Pathological Study of Periarteritis Nodosa : A Report of Five Cases, One Histologically Healed. Am J Pathol 1930 ; 6 (4) : 401-26
13) 尾崎承一ほか. 循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告). 血管炎症候群の診療ガイドライン. V. 結節性多発動脈炎. Circ J 2008 ; 72 (Suppl IV) : 1336-40
15) Guillevin L, Jarrousse B, Lok C et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991 ; 18 (4) : 567-74
18) 難病医学研究財団/ 難病情報センター. 免疫疾患調査研究班 (難治性血管炎に関する調査研究班) : (IVCY治療における年齢, 腎機能に応じたシクロホスファミドの投与量設定表)
19) de Menthon M, Mahr A. Treating polyarteritis nodosa : current state of the art. Clin Exp Rheumatol 2011 ; 29 (1 Suppl 64) : S110-16
28) Guillevin L, Lhote F, Leon A et al. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 1993 ; 20 (2) : 289-98
P.361 掲載の参考文献
5) 尾崎承一, 槇野博史, 松尾清一 (編). ANCA関連血管炎の診療ガイドライン. 厚生労働省難治性疾患克服研究事業, 2011
11) Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994 ; 87 (11) : 671-8
22) Koldingsnes W, Nossent JC et al. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003 ; 30 (1) : 80-88
46) 松田朝子, 有村義宏, 吉原 堅ほか. 好酸球性多発血管炎性肉芽腫症 (Churg-Strauss症候群) 寛解期の末梢神経障害に対する大量γグロブリン療法の有効性. 日本臨床免疫学会会誌 2013 ; 36 (4) : 217-25
P.367 掲載の参考文献
23) Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol 1998 ; 49 (1) : 9-14
29) Carter ER, Guevara JP, Moffitt DR. Pulmonary hemorrhage in an adolescent with Henoch-Schonlein purpura. West J Med 1996 ; 164 (2) : 171-3
33) Olson JC, Kelly KJ, Pan CG et al. Pulmonary disease with hemorrhage in Henoch-Schoenlein purpura. Pediatrics 1992 ; 89 (6 Pt 2) : 1177-81
49) Topaloglu R, Sungur A, Baskin E et al. Vascular endothelial growth factor in Henoch-Schonlein purpura. J Rheumatol 2001 ; 28 (10) : 2269-73
50) Lin CY, Yang YH, Lee CC et al. Thrombopoietin and interleukin-6 levels in Henoch-Schonlein purpura. J Microbiol Immunol Infect 2006 ; 39 (6) : 476-82

11章 結晶誘発性関節炎

P.378 掲載の参考文献
2) 川崎拓, 七川歡次. 住民検診による痛風の疫学調査. 痛風と核酸代謝 2006 ; 30 : 66
3) 川崎拓. リウマチ病セミナー XVIII 第1版. 七川歓次 (監修). 永井書店, 2007, 51-57
4) Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis 2010 ; 68 (3) : 199-203
9) Urano W, Yamanaka H, Tsutani H et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 2002 ; 29 (9) : 1950-3
13) 日本痛風・核酸代謝学会ガイドライン改訂委員会 (編). 高尿酸血症・痛風の治療ガイドライン 第2版. メディカルレビュー社, 2011
15) Werlen D, Gabay C, Vischer TL et al. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis : an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed 1996 ; 63 (4) : 248-54
16) Fernandez C, Noguera R, Gonzalez JA et al. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999 ; 26 (10) : 2285-6
P.386 掲載の参考文献
1) HOLLANDER JL, JESSAR RA, McCARTY DJ. Synovianalysis : an aid in arthritis diagnosis. Bull Rheum Dis 1961 ; 12 : 263-4
35) Filippucci E, Scire CA, Delle Sedie A et al. Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease. Clin Exp Rheumatol 2010 ; 28 (1) : 2-5
37) Salaffi F, De Angelis R, Grassi W et al. Prevalence of musculoskeletal conditions in an Italian population sample : results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol 2005 ; 23 (6) : 819-28
45) Salaffi F, Carotti M, Guglielmi G et al. The crowned dens syndrome as a cause of neck pain : clinical and computed tomography study in patients with calcium pyrophosphate dihydrate deposition disease. Clin Exp Rheumatol 2008 ; 26 (6) : 1040-46

12章 その他の疾患

P.397 掲載の参考文献
4) 水木信久, 後藤浩, 大野重昭ほか. ベーチェット病眼病変診療ガイドライン. 厚生労働省研究費補助金 難治性疾患克服研究事業 ベーチェット病に関する調査研究. 平成20~22年度 総括・分担報告書 (研究代表者 石ヶ坪良明), 2011 ; 195-226
5) 廣畑俊成, 菊地弘敏, 桑名正隆ほか. 神経ベーチェット病の診断基準作成に関する研究. 厚生労働省研究費補助金 難治性疾患克服研究事業 ベーチェット病に関する調査研究. 平成20~22年度 総括・分担報告書 (研究代表者 石ヶ坪良明). 2011 ; 237-39
6) Hisamatsu T, Ueno F, Matsumoto T et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFα monoclonal antibodies. J Gastroenterol 2014 ; 49 (1) : 156-62
10) Ideguchi H, Suda A, Takeno M et al. Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 2011 ; 29 (4 Suppl 67) : S47-53
23) BenEzra D, Cohen E, Chajek T et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 1988 ; 20 (3 Suppl 4) : 136-43
25) Ohno S, Nakamura S, Hori S et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 (7) : 1362-8
29) Deuter CM, Zierhut M, Mohle A et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum 2010 ; 62 (9) : 2796-805
30) Aktulga E, Altac M, Muftuoglu A et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980 ; 65 (3) : 399-402
36) Cantini F, Salvarani C, Niccoli L et al. Treatment of thrombophlebitis of Behcet's disease with low dose cyclosporin A. Clin Exp Rheumatol 1999 ; 17 (3) : 391-2
41) Nitecki SS, Ofer A, Karram T et al. Abdominal aortic aneurysm in Behcet's disease : new treatment options for an old and challenging problem. Isr Med Assoc J 2004 ; 6 (3) : 152-5
53) Iwata S, Saito K, Yamaoka K et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011 ; 21 (2) : 184-91
57) Tada Y, Koarada S, Haruta Y et al. The association of Behcet's disease with myelodysplastic syndrome in Japan : a review of the literature. Clin Exp Rheumatol 2006 ; 24 (5 Suppl 42) : S115-9
66) Gul A, Tugal-Tutkun I, Dinarello CA et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease : an open-label pilot study. Ann Rheum Dis 2012 ; 71 (4) : 563-6
P.403 掲載の参考文献
2) 岡寛, 山野嘉久, 遊道和男ほか. 再発性多発軟骨炎の全国疫学調査. リウマチ科 2010 ; 44 (3) : 381-3
3) Balsa A, Expinosa A, Cuesta M et al. Joint symptoms in relapsing polychondritis. Clin Exp Rheumatol 1995 ; 13 (4) : 425-30
5) Esdaile J, Hawkins D, Gold P et al. Vascular involvement in relapsing polychondritis. Can Med Assoc J 1977 ; 116 (9) : 1019-22
6) Lang-Lazdunski L, Hvass U, Paillole C et al. Cardiac valve replacement in relapsing polychondritis. A review. J Heart Valve Dis 1995 ; 4 (3) : 227-35
15) Park J, Gowin KM, Schumacher HR Jr. Steroid sparing effect of methotrexate in relapsing polychondritis. J Rheumatol 1996 ; 23 (5) : 937-8
31) Carrion M, Giron JA, Ventura J et al. Airway complications in relapsing polychondritis. J Rheumatol 1993 ; 20 (9) : 1628-9
P.413 掲載の参考文献
32) 高橋裕樹, 山本元久. IgG4関連疾患. シェーグレン症候群の診断と治療マニュアル, 日本シェーグレン症候群研究会 (編), 住田孝之, 江口勝美 (監修), 診断と治療社, 2009, 172-84
33) 日本膵臓学会・厚生労働省難治性膵疾患に関する調査研究班. 自己免疫性膵炎臨床診断基準 2011. 膵臓 2012 ; 27 : 17-25
39) Yamamoto M. IgG4-related dacryoadenitis and sialadenitis (Mikulicz's disease). Mod Rheumatol 2013 ; 23 (Suppl) : S17-3

最近チェックした商品履歴

Loading...